MX2017015373A - COMPOSICIONES Y Mí‰TODOS PARA LA DEGRADACIí“N DE PROTEíNAS MAL PLEGADAS. - Google Patents

COMPOSICIONES Y Mí‰TODOS PARA LA DEGRADACIí“N DE PROTEíNAS MAL PLEGADAS.

Info

Publication number
MX2017015373A
MX2017015373A MX2017015373A MX2017015373A MX2017015373A MX 2017015373 A MX2017015373 A MX 2017015373A MX 2017015373 A MX2017015373 A MX 2017015373A MX 2017015373 A MX2017015373 A MX 2017015373A MX 2017015373 A MX2017015373 A MX 2017015373A
Authority
MX
Mexico
Prior art keywords
compositions
methods
degradation
misfolded proteins
proteins
Prior art date
Application number
MX2017015373A
Other languages
English (en)
Inventor
Guo Lili
Yang Xiaolu
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2017015373A publication Critical patent/MX2017015373A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invención se relaciona con composiciones y métodos para promover la degradación de proteí­nas mal plegadas y agregados de proteí­na; las composiciones y métodos se pueden usar para tratar un trastorno asociado con proteí­nas mal plegadas o agregados de proteí­na; en ciertas instancias, las composiciones y métodos se relacionan con moduladores de una o más proteí­nas TRIM o una o más STUbLs.
MX2017015373A 2015-05-29 2016-05-27 COMPOSICIONES Y Mí‰TODOS PARA LA DEGRADACIí“N DE PROTEíNAS MAL PLEGADAS. MX2017015373A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562168309P 2015-05-29 2015-05-29
PCT/US2016/034751 WO2016196328A1 (en) 2015-05-29 2016-05-27 Compositions and methods for degradation of misfolded proteins

Publications (1)

Publication Number Publication Date
MX2017015373A true MX2017015373A (es) 2018-07-06

Family

ID=57441753

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017015373A MX2017015373A (es) 2015-05-29 2016-05-27 COMPOSICIONES Y Mí‰TODOS PARA LA DEGRADACIí“N DE PROTEíNAS MAL PLEGADAS.
MX2021014954A MX2021014954A (es) 2015-05-29 2017-11-29 Composiciones y metodos para la degradacion de proteinas mal plegadas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014954A MX2021014954A (es) 2015-05-29 2017-11-29 Composiciones y metodos para la degradacion de proteinas mal plegadas.

Country Status (15)

Country Link
US (2) US11542500B2 (es)
EP (1) EP3302706A4 (es)
JP (2) JP7011467B2 (es)
KR (1) KR20180011276A (es)
CN (1) CN108271364A (es)
AU (2) AU2016271635B2 (es)
BR (1) BR112017025574A2 (es)
CA (1) CA2987057A1 (es)
HK (1) HK1252757A1 (es)
IL (2) IL255912B2 (es)
MX (2) MX2017015373A (es)
RU (2) RU2021134920A (es)
SG (1) SG10202011833TA (es)
WO (1) WO2016196328A1 (es)
ZA (1) ZA201708067B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202007103TA (en) 2014-11-05 2020-09-29 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
CA3024448A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Modulatory polynucleotides
CN110753557B (zh) * 2017-03-22 2024-03-22 神济昌华(北京)生物科技有限公司 Trim72通过泛素化fus蛋白突变体作为als的潜在治疗性靶标
AU2018261790A1 (en) 2017-05-05 2019-11-28 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN109609614B (zh) * 2017-09-30 2022-07-15 首都医科大学附属北京胸科医院 检测trim2、trim4、trim32和/或trim46基因或蛋白产品的用途
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP3697905A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN108018303A (zh) * 2017-12-20 2018-05-11 江苏浩欧博生物医药股份有限公司 一种人Ro52重组蛋白的制备方法
EP3765077A4 (en) * 2018-03-14 2022-01-05 Technion Research & Development Foundation Limited PROGNOSTIC BIOMARKER IN CANCER
US11147815B2 (en) 2018-08-21 2021-10-19 Synkrino Biotherapeutics, Inc. Compositions and methods for treating diseases associated with uncontrolled inflammatory responses
US20210369731A1 (en) * 2018-10-09 2021-12-02 The Regents Of The University Of California Covalent targeting of e3 ligases
EP3966227A1 (en) * 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN110302383A (zh) * 2019-07-29 2019-10-08 深圳先进技术研究院 Trim11基因和蛋白靶点以及抑制剂在乳腺癌中的用途
CN110669791B (zh) * 2019-10-29 2020-08-04 成都益安博生物技术有限公司 一种提高细胞抗体表达量的方法
KR102114880B1 (ko) * 2020-01-15 2020-05-26 서울대학교병원 코돈 최적화된 TIF1γ 폴리뉴클레오티드를 포함하는 재조합 벡터 및 이의 용도
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
CN113292658B (zh) * 2021-04-17 2023-02-28 复旦大学 一种融合蛋白及其在靶向降解细胞内蛋白中的应用
CN113651879A (zh) * 2021-08-18 2021-11-16 武汉华美生物工程有限公司 一种trim21全长蛋白的制备方法及应用
CN117159747A (zh) * 2023-08-30 2023-12-05 暨南大学 一种亨廷顿舞蹈症的药物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010027182A1 (en) 1998-05-29 2001-10-04 Huda Y. Zoghbi Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfilind in sca1
WO2001090342A2 (en) 2000-05-22 2001-11-29 Johns Hopkins University Genetic engineering of vascular grafts to resist disease
US20040235733A1 (en) 2003-02-27 2004-11-25 Steffan Joan S. Methods and reagents for reducing polyglutamine toxicity
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
WO2005081911A2 (en) * 2004-02-25 2005-09-09 Dana-Farber Cancer Institute, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5α
US20140056873A1 (en) 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
NZ563003A (en) 2005-04-27 2011-03-31 Univ Florida Use of a farnesyl transferase inhibitor to enhance autophagic protein degradation in protein conformation disorders
EP1870107A1 (en) 2006-06-23 2007-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases
US7785857B2 (en) 2006-08-31 2010-08-31 Saint Louis University Protein C variant
AU2010204723A1 (en) * 2009-01-14 2011-08-18 The Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases
CA2833908C (en) * 2010-04-23 2021-02-09 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
GB201012410D0 (en) * 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
US9060507B2 (en) 2010-09-01 2015-06-23 Perfusion Fluid Technologies Inc Perfusion solution
CN103127492A (zh) * 2011-11-23 2013-06-05 中国科学院上海巴斯德研究所 一种抗丙型肝炎病毒的蛋白及其用途
US10253099B2 (en) * 2012-12-05 2019-04-09 Ruprecht-Karls-Universität Heidelberg Conjugates of proteins and multivalent cell-penetrating peptides and their uses
WO2016054554A1 (en) * 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs

Also Published As

Publication number Publication date
AU2022200673A1 (en) 2022-02-24
RU2761564C9 (ru) 2022-03-17
JP7011467B2 (ja) 2022-02-10
JP2018521014A (ja) 2018-08-02
CA2987057A1 (en) 2016-12-08
SG10202011833TA (en) 2021-01-28
EP3302706A1 (en) 2018-04-11
AU2016271635A1 (en) 2018-01-25
US20230313190A1 (en) 2023-10-05
ZA201708067B (en) 2018-11-28
KR20180011276A (ko) 2018-01-31
RU2017144862A3 (es) 2019-11-20
IL255912A (en) 2018-01-31
RU2761564C2 (ru) 2021-12-10
JP2022000459A (ja) 2022-01-04
MX2021014954A (es) 2022-01-31
BR112017025574A2 (pt) 2018-08-14
WO2016196328A1 (en) 2016-12-08
HK1252757A1 (zh) 2019-05-31
CN108271364A (zh) 2018-07-10
IL255912B1 (en) 2023-06-01
AU2016271635B2 (en) 2021-11-04
IL302965A (en) 2023-07-01
IL255912B2 (en) 2023-10-01
US20180163202A1 (en) 2018-06-14
RU2021134920A (ru) 2022-04-15
RU2017144862A (ru) 2019-07-02
US11542500B2 (en) 2023-01-03
EP3302706A4 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
MX2021014954A (es) Composiciones y metodos para la degradacion de proteinas mal plegadas.
AU2017260389A1 (en) Chimeric neurotoxins
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12017502180A1 (en) Tau-binding antibodies
MY197345A (en) Antibody molecules to april and uses thereof
NZ725568A (en) Modified j-chain
BR112017006664A2 (pt) terapias de combinação
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
AU2016263598A8 (en) Methods and kits for treating depression
PH12017502207A1 (en) Tau-binding antibodies
MX2023008211A (es) Composiciones y metodos para disminuir la expresion de tau.
MX2016009428A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
PH12017501864A1 (en) Compositions and methods for treating autism
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2015008310A (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
WO2017096431A8 (en) Proteinaceous molecules and methods of use
IL264380A (en) Increased fertility in cattle breeds
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
MX2015009907A (es) Metodo para tratar y curar leishmaniosis usando fexinidazol.
EP3253400A4 (en) Oleanoyl peptide composition and collagen enhancement